2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatment
2010
SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals
Esterlis I, Cosgrove KP, Petrakis IL, McKee SA, Bois F, Krantzler E, Stiklus SM, Perry EB, Tamagnan GD, Seibyl JP, Krystal JH, Staley JK. SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals. Drug And Alcohol Dependence 2010, 108: 146-150. PMID: 20074869, PMCID: PMC2871672, DOI: 10.1016/j.drugalcdep.2009.12.006.Peer-Reviewed Original ResearchConceptsDrinks/occasionNicotinic acetylcholine receptorsControl nonsmokersAcetylcholine receptorsHeavy drinkersHeavy drinkingLast alcoholic beverageHeavy alcohol drinkersHeavy alcoholSingle photon emissionSeverity of drinkingEffect of ageTobacco smokingAlcohol drinkersAlcohol drinkingCommon neural substrateNonsmokersAlcohol consumptionReceptor availabilityLarger studyAlcohol drinksAlcohol use behaviorsAddictive disordersDrinkersNeural substrates